Albuminuriab, n (%) | 62 (13.6) | 30 (3.6) | <0.001 |
|
eGFR, n (%) | | | <0.001 |
≥90 ml/min/1.73 m2 | 137 (30) | 146 (18) | |
60–89 | 238 (52) | 540 (65) | |
45–59 | 64 (14) | 128 (15) | |
30–44 | 14 (3.1) | 18 (2.2) | |
15–29 | 2 (0.4) | 4 (0.5) | |
<15 | 0 | 0 | |
|
Chronic kidney disease, n (%) | | | <0.001 |
Stage 1: eGFR ≥90 + albuminuria | 21 (4.6) | 2 (0.2) | |
Stage 2: eGFR 60–89 + albuminuria | 25 (5.5) | 24 (2.9) | |
Stage 3a: eGFR 45–59 | 64 (14.0) | 128 (15.3) | |
Stage 3b: eGFR 30–44 | 14 (3.1) | 18 (2.2) | |
Stage 4: eGFR 15–29 | 2 (0.4) | 4 (0.5) | |
Stage 5: eGFR <15 or kidney replacement therapy | 0 | 0 | |
|
Total chronic kidney disease, n (%) |
(stage 1–5) | 125 (27.5) | 176 (21.1) | |